SCHEMBL983844

SCHEMBL983844

CCOC(=O)c1n[nH]cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
XBP1 P17861 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TLR9 Q9NR96 1/20 0.47
KDM4E B2RXH2 4/20 0.46
GLP1R P43220 1/20 0.46
POLB P06746 1/20 0.45
PDE4D Q08499 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
ALPL P05186 1/20 0.42
TARBP2 Q15633 1/20 0.42
RAB9A P51151 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719025 0.81 KDM4E (0.49) L3MBTL1MAPTALDH1A1MAPK1KDM4E
SCHEMBL3376695 0.80 KDM4E (0.51) L3MBTL1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL946588 0.80 KDM4E (0.47) L3MBTL1MAPTALDH1A1KDM4EPOLB
SCHEMBL983024 0.79 NPSR1 (0.46) L3MBTL1MAPTALDH1A1MAPK1NPSR1
SCHEMBL16235771 0.79 KDM4E (0.46) L3MBTL1NPC1MAPTALDH1A1TP53
SCHEMBL953967 0.79 KDM4E (0.46) L3MBTL1NPC1MAPTALDH1A1HTT
SCHEMBL6837256 0.79 KDM4E (0.46) L3MBTL1MAPTALDH1A1MAPK1KDM4E
SCHEMBL1431096 0.79 KDM4E (0.46) L3MBTL1NPC1MAPTNPSR1KDM4E
SCHEMBL31728192 0.77 POLB (0.48) L3MBTL1NPC1MAPTALDH1A1HTT
SCHEMBL16559320 0.77 POLB (0.48) L3MBTL1MAPTALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 US disclosed
CN-120040475-A Compounds as WRN inhibitors and uses thereof 南京圣和药业股份有限公司 2025-05-27 CN disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 CN disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 CN disclosed
EP-2531490-B1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2014-10-15 EP disclosed
US-8835444-B2 Cyclohexyl amide derivatives as CRF receptor antagonists NOVARTIS AG (CH) 2014-09-16 US disclosed
US-20120316185-A1 Cyclohexyl Amide Derivatives as CRF Receptor Antagonists NOVARTIS AG (CH) 2012-12-13 US disclosed
EP-2531490-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS Novartis AG (CH) 2012-12-12 EP disclosed
WO-2011095450-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-11 WO disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
WO-2009123714-A2 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2009-10-08 WO disclosed
WO-2009123714-A2 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316185-A1 Cyclohexyl Amide Derivatives as CRF Receptor Antagonists CRHR2, CRHR1, CRH L3MBTL1 4588/4885NPC1 1676/4885MAPT 3950/4885
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 L3MBTL1 3455/4885NPC1 1136/4885MAPT 1905/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB L3MBTL1 2905/4885NPC1 1287/4885MAPT 1843/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB L3MBTL1 2905/4885NPC1 1287/4885MAPT 1843/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB L3MBTL1 2905/4885NPC1 1287/4885MAPT 1843/4885
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR5A, HTR2A, HTR3A L3MBTL1 4884/4885NPC1 3826/4885MAPT 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.